Antengene Corporation Limited (HKG:6996)

Market Cap	4.08B +71.4%
Revenue (ttm)	117.22M +14.6%
Net Income	-266.11M
EPS	-0.42
Shares Out	679.24M
PE Ratio	n/a
Forward PE	12.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,601,375
Average Volume	3,342,334
Open	6.08
Previous Close	6.00
Day's Range	5.79 - 6.08
52-Week Range	2.48 - 8.16
Beta	0.34
RSI	74.77
Earnings Date	Mar 20, 2026

About Antengene Corporation

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 129
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6996

Financial Performance

In 2025, Antengene Corporation's revenue was 105.34 million, an increase of 14.56% compared to the previous year's 91.95 million. Losses were -239.13 million, -25.10% less than in 2024.

Financial numbers in CNY